Search results
Showing 16 to 30 of 347 results for clinical reference medicine & health
In development Reference number: GID-TA11052 Expected publication date: 17 February 2027
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]
In development Reference number: GID-TA11886 Expected publication date: 13 May 2027
Intravenous fluid therapy in children and young people in hospital (NG29)
This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy. It applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions. This guideline represents a major opportunity to improve patient safety for children and young people having IV fluid therapy in hospital.
This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
Sole supplied titles are distinct journal and book collections that can be purchased from Lot 1 of our purchasing framework.
This quality standard covers the organisation and delivery of emergency and acute medical care in the community and in hospital. It covers adults (16 and over) who seek, or are referred for, emergency NHS care for a suspected or confirmed acute medical emergency. It describes high-quality care in priority areas for improvement.
View quality statements for QS174Show all sections
Sections for QS174
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST34)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Preventing suicide in community and custodial settings (NG105)
This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to:
Our events help you meet experts and stay connected with peers.
This quality standard covers the initial management of self-harm and the provision of longer-term support for children and young people (aged 8 to 18) and adults (aged 18 and over) who self-harm. It describes high-quality care in priority areas for improvement.
View quality statements for QS34Show all sections
Sections for QS34
- Quality statements
- Quality statement 1: Compassion, respect and dignity
- Quality statement 2: Initial assessments
- Quality statement 3: Psychosocial assessments
- Quality statement 4: Observation
- Quality statement 5: Safe physical environments
- Quality statement 6: Care plans
- Quality statement 7: Psychological interventions
This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process
This guideline covers mental health rehabilitation for adults with complex psychosis. It aims to ensure people can have rehabilitation when they need it and promotes a positive approach to long-term recovery. It includes recommendations on organising rehabilitation services, assessment and care planning, delivering programmes and interventions, and meeting people’s physical healthcare needs.
Disease-specific reference case extension: management of overweight and obesity in adults (PMG50)
This NICE disease-specific reference case extension describes standardised methods for health economic evaluations of interventions for managing overweight and obesity in adults. For further details on developing and implementing disease-specific reference case extensions, see NICE’s position statement on use of disease-specific reference models in economic evaluations